clinical trial · NCT07474727
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Colorectal CancerAMT-6765-FULeucovorinBevacizumabCetuximabIrinotecanOxaliplatin
brief summary
This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced colorectal cancer, and to assess the PK(Pharmacokinetic) characteristics and immunogenicity of AMT-676.
started
Apr 1, 2026
primary completion
Sep 30, 2027
completion
Feb 28, 2028
last updated
Mar 16, 2026
official title
An Phase II Study Evaluating the Safety and Efficacy of AMT-676 in Combination With 5-fluorouracil, Leucovorin, Bevacizumab (or Cetuximab) in Participants of Advanced Colorectal Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol